Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

Inclusion Criteria:

1. Patients who provide written informed consent form (ICF) to participate in thestudy.

2. Male and female.

3. ≥ 18 years old.

4. Diagnosis of moderate or severe HS (Hurley stage and IHS4).

5. Patient who initiated treatment with secukinumab no longer than 4 weeks prior towritten ICF.

6. Decision for secukinumab prescription was made by the attending physician accordingto the approved national label during routine clinical practice, regardless of studyparticipation.

Exclusion Criteria:

1. Any medical or psychological condition that may prevent the study participation,based on practitioners' decision-making.

2. Participation in an ongoing clinical trial.

3. Known or suspected severe hypersensitivity for secukinumab, formulation excipients,or injection device components (i.e., latex).

4. Clinically significant infection exacerbation, including active tuberculosis.

5. Patients with active inflammatory bowel disease (IBD).

6. Age <18 years.

7. Pregnancy and breastfeeding.

8. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.